Trevena (TRVN) Earns News Impact Score of -0.02

Headlines about Trevena (NASDAQ:TRVN) have trended somewhat negative this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trevena earned a news impact score of -0.02 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.3899226475407 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern’s scoring:

Trevena (TRVN) traded down 0.65% during midday trading on Friday, hitting $1.54. 761,697 shares of the stock traded hands. The stock’s market cap is $91.93 million. Trevena has a one year low of $1.43 and a one year high of $8.00. The company has a 50-day moving average price of $2.28 and a 200 day moving average price of $2.60.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.35). Equities research analysts anticipate that Trevena will post ($1.36) earnings per share for the current year.

Several equities analysts recently issued reports on TRVN shares. HC Wainwright cut their price target on shares of Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Barclays PLC lowered shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $15.00 to $2.50 in a report on Monday, October 16th. Oppenheimer Holdings, Inc. set a $5.00 price target on shares of Trevena and gave the stock a “buy” rating in a report on Thursday, October 12th. Zacks Investment Research lowered shares of Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $10.00 price target on shares of Trevena in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.25.

TRADEMARK VIOLATION NOTICE: “Trevena (TRVN) Earns News Impact Score of -0.02” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with's FREE daily email newsletter.

Leave a Reply